Skip to main content

Epic Sciences Gets Phase II SBIR Grant for Lung Cancer Assay Development

NEW YORK (GenomeWeb News) – Epic Sciences today said that it has received a Phase II Small Business Innovation Research award from the National Cancer Institute and the National Institutes of Health to develop a lung cancer assay.

The test would identify and characterize circulating tumor cells in lung cancer patients.

The contract follows a Phase I SBIR grant, under which Epic developed a "clinically useful and commercially relevant method for identifying and enumerating CTCs." Under the new award, the San Diego-based firm will finalize the diagnostic test and validate it clinically in patients with suspected lung cancer.

Epic said that the Phase I and II grants together provided the firm with $1.2 million.

"The lungs are sensitive and difficult tissues to access for biopsies and, as a result, many patients lack adequate biopsy material for diagnostic testing," David Nelson, president and CEO of Epic Sciences, said in a statement. "A blood test for lung cancer could provide a better tolerated, less risky, and more effective strategy for diagnosing lung cancer patients."

Nelson also noted that the test also will be designed to characterize circulating tumor cells to help guide personalized treatment options.

Privately held Epic recently raised $13 million in a Series B financing round.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.